Treatment of Unifocal Langerhans Cell Histiocytosis in Adults Without Diabetes Insipidus
This page covers the management of adults presenting with unifocal Langerhans cell histiocytosis — a solitary lesion involving any organ — in the absence of diabetes insipidus.
Unifocal LCH is characterised by a single lesion and is distinguished from single-system multifocal disease, which involves more than one lesion. In adults without diabetes insipidus, this presentation forms a specific subgroup that informs the choice of first-line approach.
First-line management in this setting centres on observation or a localised intervention — the specific modality depends on lesion site and clinical factors. The full protocol specifies which options apply and under what circumstances each is selected.
The primary measure of response is resolution of the LCH lesion on imaging, assessed at 2–3 months after initiation of management.
References
DOI: 10.1182/blood.2021014343
- The proposed classification system differentiates between unifocal (solitary lesion) and single-system multifocal disease (>1 lesion).
- For unifocal LCH (except DI), observation or local therapies such as surgical excision, intralesional steroids, or radiation are recommended as first-line treatments.
- Surgical resection may be preferred depending on the disease location but should only be attempted if not heroic or mutilating.
- Depending on the location, intralesional corticosteroid therapy (eg, methylprednisone or triamcinolone) or, especially in the case of an accompanying soft tissue component, radiation therapy (eg, 10-20 Gy) may offer an excellent and durable response.
- Other unifocal LCH FDG-PET/CT or CT/MRI in 2-3 mo.